Long COVID Prevalence and the Impact of the Third SARS-CoV-2 Vaccine Dose: A Cross-Sectional Analysis from the Third Follow-Up of the Borriana Cohort, Valencia, Spain (2020-2022).

Vaccines (Basel) · 2023 · PMC10611325 · PMID 37896992

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

a significant trendp = 0.0010actually significant

We observed the prevalence of long COVID to increase with advancing age, with a proportion of 10.0% (7 out of 70) in the 18 to 24 age group, 29.4% (74 out of 252) in the 25 to 49 age group, and 34.4% (52 out of 151) in the 50 to 64 age group, with a significant trend for age ( p = 0.0010).

also in 1,253 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.